🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Adria Suarez Mora

University of Pittsburgh

ORCID: 0000-0002-2996-7755

Also affiliated with Magee-Womens Research Institute, Magee-Womens Hospital

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity”.

Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3659
N/A
1.7DataRank · unranked
34 citations

Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana +11 more

Longitudinal Modulation of Loco-Regional Immunity in Ovarian Cancer Patients Receiving Intraperitoneal Chemotherapy

Cancers(2022)10.3390/cancers14225647
N/A
0DataRank · unranked
5 citations

Mary Strange, Yusi Fang, Ibrahim Uygun, Lixin Zhang, George C. Tseng +4 more

Characterization of three distinct treatment groups in women with small bowel obstructions and gynecologic malignancies: conservative, operative, and palliative management

Clinical Obstetrics Gynecology and Reproductive Medicine(2022)10.15761/cogrm.1000341
N/A
0DataRank · unranked
0 citations

Alison Zeccola, Adria Suarez Mora, Zainab Balogun, Phillip Grosse, Li Wang +2 more

Data from Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

(2023)10.1158/1078-0432.c.6532676
N/A
0DataRank · unranked
0 citations

Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana +11 more

Data from Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

(2023)10.1158/1078-0432.c.6532676.v1
N/A
0DataRank · unranked
0 citations

Haider Mahdi, Yusi Fang, Mary Strange, Ibrahim Uygun, Mainpal Rana +11 more